As the COVID-19 curve flattens in the United States, medical experts and policymakers discuss what to expect throughout the remainder of the year and what will be necessary to resume daily life.
Base editing by nucleotide deaminases linked to programmable DNA-binding proteins represents a promising approach to permanently remedy blood disorders, although its application in engrafting hematopoietic stem cells (HSCs) remains unexplored. In this study, we purified A3A (N57Q)-BE3 base editor for ribonucleoprotein (RNP) electroporation of human-peripheral-blood-mobilized CD34+ hematopoietic stem and progenitor cells (HSPCs). We observed frequent on-target cytosine base edits at the BCL11A erythroid enhancer at +58 with few indels. Fetal hemoglobin (HbF) induction in erythroid progeny after base editing or nuclease editing was similar. A single therapeutic base edit of the BCL11A enhancer prevented sickling and ameliorated globin chain imbalance in erythroid progeny from sickle cell disease and β-thalassemia patient-derived HSPCs, respectively. Moreover, efficient multiplex editing could be achieved with combined disruption of the BCL11A erythroid enhancer and correction of the HBB -28A>G promoter mutation. Finally, base edits could be produced in multilineage-repopulating self-renewing human HSCs with high frequency as assayed in primary and secondary recipient animals resulting in potent HbF induction in vivo. Together, these results demonstrate the potential of RNP base editing of human HSPCs as a feasible alternative to nuclease editing for HSC-targeted therapeutic genome modification.
- May | 13 | 2020
- May | 1 | 2020
John Iafrate, MD, PhD, and Edward Ryan, MD, break down the basics about antibodies, serology testing and the potential implications of a positive antibody presence in the case of COVID-19.
- May | 1 | 2020
John Iafrate, MD, PhD, y Edward Ryan, MD, desglosan los fundamentos sobre anticuerpos, pruebas de serología y las posibles implicaciones de una presencia positiva de anticuerpos en el caso del COVID-19.
- Mar | 16 | 2020